Table 5 Grading of recommendations, assessment, development, and evaluation approach.
Certainty assessment | Number of patients | Effect | Certainty | Importance | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Number of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Intervention group | Control group | Absolute (95% CI) | ||
FIQ score | |||||||||||
5 | RCT | Seriousa | Seriousb | Not serious | Not serious | None | 79 | 75 | SMD: 0.64 lower (1.21 lower to 0.08 lower) | ⨁⨁◯◯ Low | IMPORTNT |
Pain score | |||||||||||
3 | RCT | Seriousa | Seriousb | Not serious | Not serious | None | 47 | 45 | SMD: 0.89 lower (1.80 lower to 0.03 higher) | ⨁⨁◯◯ Low | IMPORTANT |
Overall stability index | |||||||||||
3 | RCT | Seriousa | Seriousb | Not serious | Not serious | None | 52 | 48 | SMD: 0.55 lower (0.95 lower to 0.15 lower) | ⨁⨁◯◯ Low | IMPORTANT |
Anteroposterior stability index | |||||||||||
3 | RCT | Seriousa | Seriousb | Not serious | Not serious | None | 52 | 48 | SMD: 0.32 lower (0.73 lower to 0.08 higher) | ⨁⨁◯◯ Low | IMPORTANT |
Mediolateral stability index | |||||||||||
3 | RCT | Seriousa | Seriousb | Not serious | Not serious | None | 52 | 48 | SMD: 0.27 lower (0.67 lower to 0.12 higher) | ⨁⨁◯◯ Low | IMPORTANT |
Quality of life | |||||||||||
2 | RCT | Seriousa | Seriousb | Not serious | Not serious | None | 34 | 32 | SMD: 0.72 higher (0.61 lower to 2.04 higher) | ⨁⨁◯◯ Low | IMPORTANT |
6MWT | |||||||||||
2 | RCT | Seriousa | Seriousb | Not serious | Not serious | None | 37 | 35 | SMD: 1.65 higher (1.11 higher to 2.20 higher) | ⨁⨁◯◯ Low | IMPORTANT |
Lower body dynamic strength | |||||||||||
2 | RCT | Seriousa | Seriousb | Not serious | Not serious | None | 28 | 22 | SMD: 0.22 higher (0.34 lower to 0.78 higher) | ⨁⨁◯◯ Low | IMPORTANT |
